Apellis Pharmaceuticals, Inc. Expected to Post Q2 2025 Earnings of $0.23 Per Share (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research note issued on Tuesday, April 23rd. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.23 per share for the quarter, up from their previous estimate of $0.18. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at $0.45 EPS, Q1 2026 earnings at $1.14 EPS and FY2026 earnings at $3.59 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.73). The company had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The firm’s revenue was up 545.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.50) EPS.

Other research analysts also recently issued reports about the company. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a research note on Thursday. Raymond James upped their price target on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research note on Thursday, January 11th. The Goldman Sachs Group boosted their price objective on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, January 9th. Oppenheimer boosted their price objective on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $81.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $77.93.

Apellis Pharmaceuticals Stock Down 4.0 %

Shares of NASDAQ:APLS opened at $47.93 on Wednesday. The company has a market capitalization of $5.78 billion, a price-to-earnings ratio of -10.70 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. The business’s 50-day moving average is $58.61 and its 200-day moving average is $57.37. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75.

Insider Activity at Apellis Pharmaceuticals

In related news, insider Nur Nicholson sold 835 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $64.14, for a total value of $53,556.90. Following the transaction, the insider now owns 67,507 shares in the company, valued at $4,329,898.98. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Pascal Deschatelets sold 69,107 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares in the company, valued at $60,452,799.11. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Nur Nicholson sold 835 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $64.14, for a total value of $53,556.90. Following the sale, the insider now owns 67,507 shares in the company, valued at approximately $4,329,898.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 381,011 shares of company stock worth $23,463,657. Insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently made changes to their positions in APLS. Future Financial Wealth Managment LLC purchased a new stake in shares of Apellis Pharmaceuticals in the first quarter worth $29,000. First Horizon Advisors Inc. raised its position in shares of Apellis Pharmaceuticals by 69.0% in the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after buying an additional 265 shares in the last quarter. Covestor Ltd increased its stake in Apellis Pharmaceuticals by 564.2% in the third quarter. Covestor Ltd now owns 797 shares of the company’s stock valued at $30,000 after acquiring an additional 677 shares during the last quarter. Stephens Consulting LLC bought a new position in Apellis Pharmaceuticals in the third quarter valued at $38,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Apellis Pharmaceuticals by 29.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock valued at $115,000 after acquiring an additional 687 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).